4.6 Article

Natural Products Extracted from Fungal Species as New Potential Anti-Cancer Drugs: A Structure-Based Drug Repurposing Approach Targeting HDAC7

Journal

MOLECULES
Volume 25, Issue 23, Pages -

Publisher

MDPI
DOI: 10.3390/molecules25235524

Keywords

mushrooms; HDAC7; cancer; repositioning; structure-based virtual screening; molecular dynamics

Funding

  1. PRIN 2017 research project Novel anticancer agents endowed with multi-targeting mechanism of action [201744BN5T]
  2. MIUR [NUTRAMED PON 03PE000_78_2]
  3. EU
  4. Italian Association for Cancer Research (AIRC) [21588]

Ask authors/readers for more resources

Mushrooms can be considered a valuable source of natural bioactive compounds with potential polypharmacological effects due to their proven antimicrobial, antiviral, antitumor, and antioxidant activities. In order to identify new potential anticancer compounds, an in-house chemical database of molecules extracted from both edible and non-edible fungal species was employed in a virtual screening against the isoform 7 of the Histone deacetylase (HDAC). This target is known to be implicated in different cancer processes, and in particular in both breast and ovarian tumors. In this work, we proposed the ibotenic acid as lead compound for the development of novel HDAC7 inhibitors, due to its antiproliferative activity in human breast cancer cells (MCF-7). These promising results represent the starting point for the discovery and the optimization of new HDAC7 inhibitors and highlight the interesting opportunity to apply the drug repositioning paradigm also to natural compounds deriving from mushrooms.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available